|
1.
|
|
12 p, 940.4 KB |
An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor-induced liver injury
/
Riveiro Barciela, Mar (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Barreira-Diaz, Ana (Hospital Universitari Vall d'Hebron) ;
Salcedo, Maria-Teresa (Hospital Universitari Vall d'Hebron) ;
Callejo, Ana (Hospital Universitari Vall d'Hebron) ;
Muñoz Couselo, Eva (Hospital Universitari Vall d'Hebron) ;
Iranzo, Patricia (Hospital Universitari Vall d'Hebron) ;
Ortiz Velez, Carolina (Hospital Universitari Vall d'Hebron) ;
Cedrés, Susana (Hospital Universitari Vall d'Hebron) ;
Díaz Mejía, Nely (Hospital Universitari Vall d'Hebron) ;
Ruiz Cobo, Juan Carlos (Hospital Universitari Vall d'Hebron) ;
Morales, Rafael (Hospital Universitari Vall d'Hebron) ;
Aguilar-Company, Juan (Hospital Universitari Vall d'Hebron) ;
Zamora, Ester (Hospital Universitari Vall d'Hebron) ;
Oliveira, Mafalda (Hospital Universitari Vall d'Hebron) ;
Sanz-Martínez, María Teresa (Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Viladomiu, Lluis (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Martínez Gallo, Mónica (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ;
Buti, Maria (Universitat Autònoma de Barcelona. Departament de Medicina)
Background: There are few data on corticosteroids (CS)-sparing strategies for checkpoint inhibitor (ICI)-induced liver injury (ChILI). Aim: We aimed to assess the performance of a 2-step algorithm for severe ChILI, based on ICI temporary discontinuation (step-1) and, if lack of biochemical improvement, CS based on the degree of necroinflammation at biopsy (step-2). [...]
2024 -  10.1111/apt.17898
Alimentary Pharmacology and Therapeutics, Vol. 59 Núm. 7 (april 2024) , p. 865-876
|
|
|
2.
|
|
13 p, 368.5 KB |
Dynamic changes in circulating tumor assessed by shallow whole-genome sequencing associate with clinical efficacy of checkpoint inhibitors in
/
Carbonell, Caterina (Vall d'Hebron Institut d'Oncologia) ;
Frigola Rissech, Joan (Vall d'Hebron Institut d'Oncologia) ;
Pardo Aranda, Nuria (Vall d'Hebron Institut d'Oncologia) ;
Callejo, Ana (Vall d'Hebron Institut d'Oncologia) ;
Iranzo, Patricia (Vall d'Hebron Institut d'Oncologia) ;
Valdivia, Augusto (Vall d'Hebron Institut d'Oncologia) ;
Priano, Ilaria (Vall d'Hebron Institut d'Oncologia) ;
Cedrés, Susana (Vall d'Hebron Institut d'Oncologia) ;
Martinez-Marti, Alex (Vall d'Hebron Institut d'Oncologia) ;
Navarro, Alejandro (Vall d'Hebron Institut d'Oncologia) ;
Lenza, Laura (Vall d'Hebron Institut d'Oncologia) ;
Soleda, Mireia (Vall d'Hebron Institut d'Oncologia) ;
Gonzalo-Ruiz, Javier (Vall d'Hebron Institut d'Oncologia) ;
Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ;
Sansó, Miriam (Institut d'Investigació Sanitària Illes Balears) ;
Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Amat, Ramon (Vall d'Hebron Institut d'Oncologia) ;
Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis are the main therapeutic option for patients with advanced non-small cell lung cancer (NSCLC) without a druggable oncogenic alteration. [...]
2023 - 10.1002/1878-0261.13409
Molecular Oncology, Vol. 17 (march 2023) , p. 779-791
|
|
|
3.
|
|
6 p, 348.3 KB |
Fluorescence In Situ Hybridization and Immunohistochemistry as Diagnostic Methods for ALK Positive Non-Small Cell Lung Cancer Patients
/
Martinez, Pablo (Vall d'Hebron Institut d'Oncologia) ;
Hernandez-Losa, Javier (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Cedrés, Susana (Vall d'Hebron Institut d'Oncologia) ;
Castellvi, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Martinez-Marti, Alex (Vall d'Hebron Institut d'Oncologia) ;
Tallada, Natalia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Murtra-Garrell, Nuria (Vall d'Hebron Institut d'Oncologia) ;
Navarro, Alejandro (Vall d'Hebron Institut d'Oncologia) ;
Rodriguez-Freixinos, Victor (Vall d'Hebron Institut d'Oncologia) ;
Canela, Mercedes (Vall d'Hebron Institut d'Oncologia) ;
Ramon y Cajal, Santiago (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Felip, Enriqueta (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
Anaplastic Lymphoma Kinase (ALK) positivity represents a novel molecular target in a subset of Non-Small Cell Lung Cancers (NSCLC). We explore Fluorescence in situ Hybridization (FISH) and Immunohistochemistry (IHC) as diagnostic methods for ALK positive patients and to describe its prevalence and outcomes in a population of NSCLC patients. [...]
2013 - 10.1371/journal.pone.0052261
PloS one, Vol. 8 (january 2013)
|
|
|
4.
|
|
14 p, 572.1 KB |
Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer
/
Frigola Rissech, Joan (Vall d'Hebron Institut d'Oncologia) ;
Navarro, Alejandro (Vall d'Hebron Institut d'Oncologia) ;
Carbonell, Caterina (Vall d'Hebron Institut d'Oncologia) ;
Callejo, Ana (Vall d'Hebron Institut d'Oncologia) ;
Iranzo, Patricia (Vall d'Hebron Institut d'Oncologia) ;
Cedrés, Susana (Vall d'Hebron Institut d'Oncologia) ;
Martinez-Marti, Alex (Vall d'Hebron Institut d'Oncologia) ;
Pardo Aranda, Nuria (Vall d'Hebron Institut d'Oncologia) ;
Saoudi-Gonzalez, Nadia (Vall d'Hebron Institut d'Oncologia) ;
Martinez, Débora (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Jiménez, José (Vall d'Hebron Institut d'Oncologia) ;
Sansano, Irene (Hospital Universitari Vall d'Hebron) ;
Mancuso, Francesco M. (Vall d'Hebron Institut d'Oncologia) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Montuenga, Luis M. (Instituto de Investigación Sanitaria de Navarra) ;
Sanchez-Cespedes, Montse (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Prat, Aleix (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ;
Felip, Enriqueta (Vall d'Hebron Institut d'Oncologia) ;
Amat, Ramon (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
Immunotherapy has transformed advanced non-small cell lung cancer (NSCLC) treatment strategies and has led to unprecedented long-lasting responses in some patients. However, the molecular determinants driving these long-term responses remain elusive. [...]
2020 - 10.1002/1878-0261.12891
Molecular Oncology, 2020
|
|
|
5.
|
|
10 p, 2.7 MB |
A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer
/
Yamamoto, Nobuyuki (Wakayama Medical University. Third Department of Internal Medicine) ;
Hayashi, Hidetoshi (Kindai University Faculty of Medicine. Department of Medical Oncology) ;
Planchard, David (Institut Gustave Roussy (Villejuif, França)) ;
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Gregorc, Vanesa (IRCCS Ospedale San Raffaele. Department of Oncology, Division of Experimental Medicine) ;
Dowell, Jonathan (University of Texas Southwestern Medical Center. Department of Internal Medicine) ;
Sakai, Hiroshi (Saitama Cancer Center. Department of Thoracic Oncology) ;
Yoh, Kiyotaka (National Cancer Center Hospital East. Department of Thoracic Oncology) ;
Nishio, Makoto (The Cancer Institute Hospital of the Japanese Foundation for Cancer Research. Department of Thoracic Medical Oncology) ;
Cortot, Alexis B. (Centre Hospitalier Universitaire de Lille. Thoracic Oncology Department) ;
Benhadji, Karim A. (Taiho Oncology, Inc. Department of Clinical Development) ;
Soni, Nital (Taiho Oncology, Inc. Department of Clinical Development) ;
Huang, Jinhong (Taiho Pharmaceutical Co., Ltd. Department of Pharmacovigilance) ;
Makris, Lukas (Stathmi, Inc, 125 Brownsburg Rd, New Hope, PA 18938 USA) ;
Cedrés, Susana (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
The online version of this article (10. 1007/s10637-020-00930-5) contains supplementary material, which is available to authorized users.
2020 - 10.1007/s10637-020-00930-5
Investigational New Drugs, Vol. 38 (april 2020) , p. 1588-1597
|
|
|
6.
|
|
4 p, 1018.1 KB |
Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation
/
Cedrés, Susana (Hospital Universitari Vall d'Hebron) ;
Felip, Enriqueta (Universitat Autònoma de Barcelona) ;
Cruz, Cristina (Hospital Universitari Vall d'Hebron) ;
Martinez de Castro, Ana (Hospital Universitari Vall d'Hebron) ;
Pardo Aranda, Nuria (Universitat Autònoma de Barcelona) ;
Navarro, Alejandro (Universitat Autònoma de Barcelona) ;
Martinez-Marti, Alex (Universitat Autònoma de Barcelona) ;
Remon, Jordin (Vall d'Hebron Institut d'Oncologia) ;
Zeron-Medina, Jorge (Hospital Universitari Vall d'Hebron) ;
Balmaña Gelpí, Judith (Universitat Autònoma de Barcelona) ;
Llop-Guevara, Alba (Experimental Therapeutic Group) ;
Miquel, Josep M. (Vall d'Hebron Institut d'Oncologia) ;
Sansano, Irene (Pathology Department) ;
Nuciforo, Paolo (Molecular Oncology Group) ;
Mancuso, Francesco M (Cancer Genomic Group) ;
Serra, Violeta (Experimental Therapeutic Group) ;
Vivancos, Ana (Cancer Genomic Group)
Heat shock proteins (HSPs) are molecular chaperones that maintain proteins in their correct conformation to ensure stability and protect carcinoma cells from apoptosis. HSP90 inhibitors (HSP90i) block multiple targets simultaneously, and despite responses in a selected population, no HSP90i have yet been approved. [...]
2018 - 10.1093/jnci/djy012
Journal of the National Cancer Institute, Vol. 110 (february 2018) , p. 914-917
|
|
|
7.
|
|
7 p, 740.6 KB |
Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)
/
Martinez-Marti, Alex (Universitat Autònoma de Barcelona) ;
Felip, Enriqueta (Universitat Autònoma de Barcelona) ;
Matito, Judit (Vall d'Hebron Institut d'Oncologia) ;
Mereu, Elisabetta (Universitat Pompeu Fabra) ;
Navarro, Alejandro (Vall d'Hebron Institut d'Oncologia) ;
Cedrés, Susana (Vall d'Hebron Institut d'Oncologia) ;
Pardo Aranda, Nuria (Universitat Autònoma de Barcelona) ;
Martinez de Castro, Ana (Vall d'Hebron Institut d'Oncologia) ;
Remon, Jordin (Vall d'Hebron Institut d'Oncologia) ;
Miquel, J. M. (Vall d'Hebron Institut d'Oncologia) ;
Guillaumet-Adkins, A. (Universitat Pompeu Fabra) ;
Nadal, Ernest (Institut Català d'Oncologia) ;
Rodriguez Esteban, Gustavo (Universitat Pompeu Fabra) ;
Arqués, O. (Stem Cells and Cancer Group) ;
Fasani, R. (Vall d'Hebron Institut d'Oncologia) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Heyn, Holger (Universitat Pompeu Fabra) ;
Villanueva Garatachea, Alberto (Institut Català d'Oncologia) ;
Palmer, Héctor G (Stem Cells and Cancer Group) ;
Vivancos, Ana (Vall d'Hebron Institut d'Oncologia)
Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as osimertinib are the last line of targeted treatment of metastatic non-small-cell lung cancer (NSCLC) EGFR -mutant harboring T790M. [...]
2017 - 10.1093/annonc/mdx396
Annals of oncology, Vol. 28 (july 2017) , p. 2451-2457
|
|
|
8.
|
|
184 p, 4.3 MB |
Análisis de la expresión de PD-L1 en una serie de pacientes con mesotelioma pleural maligno
/
Cedrés, Susana ;
Felip, Enriqueta, dir. ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Introducción El mesotelioma pleural maligno (MPM) es un tumor que se caracteriza por su mal pronóstico y escasa respuesta al tratamiento, con una mediana de supervivencia de 12 meses. Se ha relacionado el asbesto como principal causante de esta enfermedad aunque recientemente se apunta a que los factores genéticos pueden tener importancia en el desarrollo del mesotelioma. [...]
Introduction Malignant pleural mesothelioma (MPM) is a rare tumor with poor prognosis and low response to treatment, with a median survival of 12 months. Asbestos has been linked as one of the main causes of the disease but recently genetics factors has been suggested play a role in MPM. [...]
[Barcelona] : Universitat Autònoma de Barcelona, 2015
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
